Difference between revisions of "Ziv-aflibercept (Zaltrap)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 9: | Line 9: | ||
*[[Colon cancer]] | *[[Colon cancer]] | ||
*[[Rectal cancer]] | *[[Rectal cancer]] | ||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 29: | Line 26: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category: | + | [[Category:Soluble decoy receptors]] |
| − | |||
| − | |||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
Revision as of 18:45, 30 January 2018
General information
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information is available in the Ziv-aflibercept (Zaltrap) package insert.[1]
- Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/31/2012: Initial FDA approval "in combination with 5-fluorouracil, leucovorin, irinotecan - ( FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen."
Also known as
- Generic names: aflibercept, VEGF trap
- Brand names: Eylea, Zaltrap